- Home
- Publications
- Publication Search
- Publication Details
Title
Angiopoietin inhibitors: A review on targeting tumor angiogenesis
Authors
Keywords
Tumor angiogenesis, Pathophysiology of tumor angiogenesis, Angiopoietins, Angiopoietin inhibitors
Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 899, Issue -, Pages 174021
Publisher
Elsevier BV
Online
2021-03-17
DOI
10.1016/j.ejphar.2021.174021
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Angiopoietins in Development of Cancer and Neoplasia Associated with Viral Infection
- (2020) Xiaolan Yu et al. Cells
- NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
- (2020) Eudocia Q. Lee et al. CANCER
- Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia
- (2020) Sylwia Bartoszewska et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
- (2019) Jayashree Sahni et al. OPHTHALMOLOGY
- Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
- (2019) Racheal G. Akwii et al. Cells
- Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
- (2019) Ignace Vergote et al. LANCET ONCOLOGY
- The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
- (2019) Johanna C. Bendell et al. ONCOLOGIST
- Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
- (2018) David M. Hyman et al. CLINICAL CANCER RESEARCH
- A critical review on ramucirumab in the treatment of advanced urothelial cancer
- (2018) Panagiotis J Vlachostergios et al. Future Oncology
- New Insights in Anti-Angiogenesis in Multiple Myeloma
- (2018) Domenico Ribatti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
- (2018) Ahmed M.E. Abdalla et al. Theranostics
- Unraveling the Role of Angiogenesis in Cancer Ecosystems
- (2018) Iratxe Zuazo-Gaztelu et al. Frontiers in Oncology
- Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
- (2018) Peter A. Kaufman et al. Clinical Breast Cancer
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
- (2017) Christian Marth et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2017) Ghassan K. Abou‐Alfa et al. ONCOLOGIST
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
- (2016) Florence T.H. Wu et al. CANCER RESEARCH
- Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- (2016) Jörg T Regula et al. EMBO Molecular Medicine
- Novel anti-angiogenic therapeutic strategies in colorectal cancer
- (2016) M. Tampellini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation
- (2016) Minah Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
- (2016) Dickran Kazandjian et al. SEMINARS IN ONCOLOGY
- Sunitinib: the antiangiogenic effects and beyond
- (2016) Zhonglin Hao et al. OncoTargets and Therapy
- The novel mechanism of lenalidomide activity
- (2015) E. C. Fink et al. BLOOD
- Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
- (2015) Véronique Diéras et al. BREAST
- Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
- (2015) Sandra P. D’ Angelo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2015) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2015) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- The discovery and development of sorafenib for the treatment of thyroid cancer
- (2015) Peter T White et al. Expert Opinion on Drug Discovery
- A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
- (2015) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
- (2015) Michael B. Atkins et al. JOURNAL OF CLINICAL ONCOLOGY
- Broad targeting of angiogenesis for cancer prevention and therapy
- (2015) Zongwei Wang et al. SEMINARS IN CANCER BIOLOGY
- Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
- (2014) Hyun-Jin Choi et al. CANCER AND METASTASIS REVIEWS
- A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
- (2014) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
- (2013) M Peeters et al. BRITISH JOURNAL OF CANCER
- Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
- (2013) Shuang Zhou et al. CURRENT MEDICINAL CHEMISTRY
- Angiopoietin signaling in the vasculature
- (2013) Lauri Eklund et al. EXPERIMENTAL CELL RESEARCH
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme
- (2013) Yasushi Soda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The Complex Role of Angiopoietin-2 in the Angiopoietin-Tie Signaling Pathway
- (2013) G. Thurston et al. Cold Spring Harbor Perspectives in Medicine
- Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
- (2012) M. M. Eatock et al. ANNALS OF ONCOLOGY
- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
- (2012) Brian Rini et al. CANCER
- Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
- (2012) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Angiopoietins in angiogenesis
- (2012) Ernesta Fagiani et al. CANCER LETTERS
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- Intussusceptive Angiogenesis: A Biologically Relevant Form of Angiogenesis
- (2012) Ward De Spiegelaere et al. JOURNAL OF VASCULAR RESEARCH
- Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
- (2011) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Chemical generation of bispecific antibodies
- (2010) V. R. Doppalapudi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of the Angiopoietins in vascular morphogenesis
- (2009) Markus Thomas et al. ANGIOGENESIS
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
- (2009) A. Morabito et al. ONCOLOGIST
- The angiogenic switch in carcinogenesis
- (2009) Vanessa Baeriswyl et al. SEMINARS IN CANCER BIOLOGY
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now